INTRODUCTION
============

Lung cancer remains a major worldwide health problem and is the leading cause of cancer mortality in both men and women.[@B1] The majority of those diagnosed have locally advanced stage III (44%) or metastatic stage IV (32%) diseases, and less than one quarter are potentially operable at diagnosis.[@B1] Generally, 75% distant metastases and 50 - 75% local recurrence occur in stage III and surgical resection, with consideration for postoperative adjuvant therapy or radiation and chemotherapy, with or without surgical resection, are evaluated to manage the disease. Disease progression within the irradiated field occurs in 33 to 50% of irradiated patients within 15 months.[@B2]-[@B4] A prominent endobronchial disease may worsen the recurrence, with symptoms of cough, obstruction, shortness of breath and severe hemoptysis. The quality of life should be improved in these patients by means of relieving the symptoms, even with a very limited expected survival. Recent advances in techniques, such as laser treatment, brachytherapy, cryotherapy, electrocautherization and intraluminal stents, have equipped the clinician with decent palliation modalities. Endobronchial radiotherapy is a well known option, with minimal complications and rapid fall off of the radiation dose, which spares the normal surrounding tissues,[@B5],[@B6] as high dose radiation is delivered to the target. Herein, our experience of palliative endobronchial radiotherapy, on 21 previously irradiated recurrent lung carcinoma patients presenting with endobronchial tumors, is assessed to evaluate efficacy of this modality.

MATERIALS AND METHODS
=====================

Twenty-one recurrent non-small cell lung carcinoma (NSCLC) patients were treated with high dose rate (HDR) endobronchial brachytherapy between January 1994 and June 1998. All patients were admitted to our department with evidence of recurrent endoluminal tumors and persistent symptoms of hemoptysis, cough and dyspnea. All patients had completed external beam thoracic radiotherapy (EBRT) at least 4 months before this study.

All patients had complete systemic and primary work-ups prior to the endobronchial brachytherapy, including a chest X-ray, complete and biochemical blood counts and chest/abdomen computerized tomography. Treatments were applied on an outpatient basis. A respiratory diseases specialist performed a flexible fiberoptic bronchoscopy, under local anesthesia, to visualize the tumor location. A hollow closed ended polyurethane afterloading catheter (5 - 6F) was then advanced beyond the site of the obstruction. Double catheters were chosen only in 2 patients due to their recurrences in carina. The position of the catheters was verified using direct X-ray films. The application was performed with a high dose rate Ir-192 afterloading system (microSelectron-Oldeft Nucletron, Netherlands). A single fraction dose of 10 Gy was prescribed to the specified area to 1 cm in 9 patients and 15 Gy in 12.

The initial performance was recorded by scoring the Karnofsky Performance Status (KPS). Patients were evaluated with the Speiser Dyspnea Index before and after the treatment ([Table 1](#T1){ref-type="table"}).[@B7]

The survival time and symptom control were calculated from the date of initiation of the endobronchial brachytherapy. Actuarial survival analyses were performed using the Kaplan-Meier method.[@B8]

RESULTS
=======

Our cohort consisted of 16 males and 5 females, with a median age of 54, ranging from 32 to 70 years. The initial diagnostic staging was stage III A in 16 and stage III B in 5 cases. Pathological diagnosis, by an endoscopic biopsy, revealed a squamous cell carcinoma in 18, an adenocarcinoma in 2 and a bronchoalveolar carcinoma in one. The recurrent diseases, detected from bronchoscopy, were as follows; 12 in the right main bronchus, 6 in the left main bronchus, 2 in the carina and 1 in the lower carina. Previous EBRT had been applied at outside institutions in all but 4 patients, leading to different radiotherapy protocols, with a median total conventional equivalent dose of 30 Gy (range, 30 - 70 Gy) ([Table 2](#T2){ref-type="table"}). In addition to EBRT, all patients had mainly received cisplatin based chemotherapy protocols before their referral to our institution.

The study group had advanced stage diseases and 5 patients (24%) had distant metastasis at the time of admission to our institute; including 2 in the adrenal glands, 2 in bone and 1 in the brain. All 21 patients had radiologically or bronchoscopicaly demonstrated intraluminal tumors, with substantial constitutional symptoms at presentation, with the exception of 2 (2/21, 9.5%) asymptomatic cases. Fourteen (66.7%) patients had severe dyspnea, with evidence of obstruction and atelectasis, which was radiologically visible in 12 (12/14, 85.7%) cases. Five patients (5/21, 24%) had severe hemoptysis that required immediate palliation. The patients demonstrated a broad range of performance stati at the time of the protocol initiation, with a mean KPS of 60, ranging from 40 to 90.

The median interval from completion of external irradiation to the onset of brachytherapy was 5.5 months, ranging from 4 to 12 months. Endobronchial treatment improved the performance and reduced symptomatology in 81% of cases (17/21) ([Table 3](#T3){ref-type="table"}). Ten of the 14 dyspneic patients recovered clinically, with radiological downstaging. Durable symptoms of shortness of breath persisted in 3 of the remaining 4 nonresponsive cases and dyspnea progressed in one patient ([Fig. 1](#F1){ref-type="fig"}). The hemoptysis in 5 patients recovered with the endobronchial brachytherapy, one patient had sudden fatal hemoptysis on the third postradiotherapy day, which was considered a brachytherapy complication.

The mean period of palliation was 45 days, ranging from 0 to 9 months. The period of palliation was significantly longer in patients with a high KPS (≥ 80) at the initial evaluation (*p* = 0.04). The median survival of all the patients was 5.5 months, ranging from 4 to 12 months. Improved survival was borderline significant in cases with a KPS ≥ 80 (*p* = 0.05).

No serious acute complications developed with the brachytherapy procedure, with the exception of 2 cases; one with fatal hemoptysis and the second with intrabronchial edema that required medical attention.

DISCUSSION
==========

Endobronchial HDR radiotherapy has been easy to apply as an outpatient procedure, with minimum complication rates, and one of the modalities used in the palliation of recurrent intraluminal tumors. Recurrent patients often present with symptoms of cough, obstruction, shortness of breath and severe hemoptysis. Endobronchial radiotherapy may be the first option in eligible recurrent lung carcinoma patients with evident endobronchial tumors. This modality has been observed as a reliable way of palliation in most of our patients.

Recurrent lung carcinoma patients, treated initially with external beam radiotherapy or chemotherapy, are generally not within curable limits. Therefore, palliation becomes the most important end point when survival concerns are absent. On the other hand, assessing the degree of palliation and quantification of symptom relief are not easy. Symptomatic relief was provided to 79% of our patients (15/19), which was reasonably comparable to other published series.[@B5],[@B6],[@B9] All patients with hemoptysis improved with the procedure, and 71% of the dyspneic cases were relieved. However, our median duration of palliation was only 45 days, which was briefly shorter than in other reports, such as the 26 weeks for Gauwitz et al, and the 4.3 months of Seagran et al.[@B5],[@B6] It was concluded that this difference in the median duration of palliation was related with the initial patient selection criteria, as the observed duration of palliation was shorter if the KPS was initially low. While patient selection is essential, endobronchial irradiation is known to be more effective and advantageous for survival when primarily considered after definite external beam irradiation.[@B7]

Brachytherapy is known as an effective palliative method for an advanced disease, either alone or combined with external radiotherapy, and has been shown to be useful with mainly a single fraction of 15 Gy.[@B10] Fractionated brachytherapy in previously irradiated recurrent patients might be an option to minimize the side effects,[@B11] but one fraction with a single bronchoscopic catheter application seems to provide lower cost and improved patient comfort, without major objective or subjective complications.

Fatal hemoptysis was experience in only one of our cases, and massive hemorrhages following endobronchial brachytherapy have been reported to range from 25 to 32% in previous studies.[@B6],[@B12] No perforation was observed during endoscopy in our subjects, which is not frequent with modern fiberoptic bronchoscopes and flexible catheters. Pneumonia, edema and bronchospasm may be evident after brachytherapy,[@B6],[@B12] and intrabronchial edema with bronchospasm was experienced in one of our patients, who was successfully medically managed. No radiation bronchitis and stenosis was detected after the treatments, which are frequently recognized as complications of brachytherapy.[@B7],[@B9]

Local treatment modalities, such as laser therapy, cryotherapy and electrocautherization, with or without brachytherapy, are also available to palliate symptoms of endobronchial lesions to obtain tumor regression and relief of obliteration.[@B13],[@B14] Implantation of airway prosthetic stents, for airway potency and palliation of bronchogenic carcinoma symptoms, has become another endoscopic option when extrinsic airway compression is evident in computed tomography or bronchoscopic evaluation for dyspnea.[@B15]-[@B17] Acute improvement of symptoms and pulmonary function after placement of an endobronchial stent for airway obstruction may be dramatic,[@B16],[@B17] but does not help hemoptysis. Transbronchoscopic laser therapy is another easily applicable alternative.[@B18] Neodymium: yttrium-aluminum-garnet (Nd : YAG) laser is used to resect endobronchial tumors to relieve symptoms. The median survival time after laser resection is about 6 months in primary tumors.[@B19] However, the requirement of general anesthesia, the increase in bleeding and anatomic deformities and the high prices are leading obstacles. Combination of palliative modalities could be an option to extend palliation duration, but the complication rates might also be increased.

In conclusion, it is our belief that high dose rate endobronchial irradiation can effectively contribute to individual palliation of recurrences in previously irradiated lung carcinoma patients if the presenting symptoms are directly related with the endobronchial tumor lacking any aid to relieve other possible symptoms related with the non-endobronchial component. Accordingly, patient selection seems to be an important parameter to accurately palliate the target patient population; and a longer duration of palliation can only be expected in patients with high performance scores. The combination of brachytherapy with other modalities, such as laser therapy or stent application, needs to be evaluated to possibly offer an effective and longer term palliation.
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